Figures & data
Figure 1 Pathways inhibited by C1-INH.
Abbreviations: C1-INH, C1 esterase inhibitor; FXI, factor XI; FXIa, activated factor XI; FXII, factor XII; FXIIa, activated factor XII; HMWK, high molecular weight kininogen; MASP, mannose-binding lectin-associated serine protease; tPA/uPA, tissue/urokinase plasminogen activator.
![Figure 1 Pathways inhibited by C1-INH.](/cms/asset/69ef65c8-56b9-4dae-bf8e-63c3884c0909/dppa_a_86379_f0001_c.jpg)
Table 1 Approval status of intravenously delivered human plasma-derived C1-INH concentrates for treatment of or prophylaxis against acute HAE attacks
Table 2 Summary of real-world observational data for home-based HAE therapy with human plasma-derived C1-INH
Table 3 Treatment-related AEs associated with commercially available human plasma-derived C1-INH concentrates for HAE treatment
Table 4 Patient eligibility criteria for home-based HAE treatment